Locust Walk Insights

 

LOCUST WALK INSIGHTS

The Asia Factor Whitepaper

How Does a Smart Deal Maker "Play" This Region and Optimize the Capital Raising and Strategic Deal Making Opportunities? Authors: Hayato Watanabe, SVP, Head of Asia Koji Hirabata, Associate Stefanie Gan, Analyst Although their biopharma ecosystem dynamics are markedly...

Trends in Venture Deal Term Sheets: Favorable Climate for Founders

If you are raising capital now, the path you are about to embark on can be stressful and littered with obstacles, but the light at the end of the tunnel is worth the trials and tribulations. Despite the inherent challenges of fundraising, the current climate is quite...

2018 Annual Trends in Medtech Transactions Report

Locust Walk is a global life sciences transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

2018 Annual Trends in Biopharma Transactions Report

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q3 2018 Trends in Biopharma Transactions Report

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q3 2018 Trends in Medtech Transaction Report

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q2 2018 Trends in Medtech Transactions Report

Each quarter, Locust Walk deal team members compile compile key statistics and performance indicators on the latest Medtech transactions. Our Q2 2018 Trends in Medtech Transactions report applies the latest data to analyze current activities in the life...

Q2 2018 Trends in Biopharma Transactions

Locust Walk is a global life science transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right...

Q1 2018 Trends in Biopharma Transactions Report

Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia.​ Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in...

Q1 2018 Trends in Medtech Transactions Report

Locust Walk is a global transaction firm serving biopharma and medtech companies in the US, Europe, and Asia.​ Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our Q1 2018 Trends in...

Let’s get digital, digital… 

Often entrepreneurs are describing their new company as a digital health start up, but what exactly is digital health?  Some incorrectly think it is anything medical with a website or connected to an iPad.  In his book, The Fourth Wave, Paul Sonnier describes it as...

Indication Selection for a Platform Company: The Faustian Dilemma

At Locust Walk, we are often tasked with addressing complex strategic business issues for our biopharma clients.  Perhaps one of the most common dilemmas is how best to optimize a given company’s clinical development strategy to maximize value.  Specifically, many...

Japan & China: So close yet so different

Having lived in Japan for more than 20 years, I have admittedly become perhaps a little too accustomed to the Japanese lifestyle. This is probably why after a few days in the hustle and bustle of Shanghai, I find myself looking forward to returning to the peace and...